Treatment of Prolactinoma with Morbid Obesity

Initial Treatment Approach

The American College of Endocrinology recommends cabergoline as the first-line treatment for prolactinoma, with standard dosing starting at 0.25 mg twice weekly and titrating up to 2 mg/week, which effectively normalizes prolactin levels in 60-83% of patients and achieves tumor shrinkage in 80-88% of cases 1, 2
Cabergoline demonstrates superior efficacy compared to bromocriptine (83% vs 59% normalization of prolactin) with a better adverse effect profile (52% vs 72% adverse events) 1, 2

For patients not responding to standard doses (up to 2 mg/week), the Endocrine Society recommends increasing cabergoline gradually to 3.5 mg/week 3, 1, 2
In exceptional cases of resistance, doses up to 7 mg/week may be considered, though evidence suggests limited additional benefit above 3.5 mg/week in adults 3, 2
Dopamine agonist resistance is defined as failure to achieve normoprolactinemia and less than 50% tumor size reduction after 3-6 months of maximally tolerated doses (at least 2 mg/week) 4, 1

The American Heart Association recommends implementing differential echocardiographic surveillance based on cabergoline dose: annual monitoring for doses >2 mg/week and every 5 years for doses ≤2 mg/week 1, 2
Monitor prolactin levels and symptoms regularly, with pituitary MRI to assess tumor response 2
Watch for cerebrospinal fluid leak (rhinorrhea) in tumors invading the sphenoid bone, which can occur after medication-induced tumor shrinkage (mean 3.3 months, range 3 days to 17 months) 3, 2
Be vigilant for dose-independent psychological side effects including mood changes, depression, aggression, hypersexuality, and impulse control disorders 4, 2

The European Society of Endocrinology recommends using small nocturnal dose increments to minimize gastrointestinal intolerance and postural hypotension 3, 1, 2
If psychological intolerance occurs, recognize that switching to alternative dopamine agonists (bromocriptine or quinagolide) will not resolve these dose-independent effects 3, 4

Following multidisciplinary discussion, offer transsphenoidal surgery when patients are unable to tolerate or remain resistant to high-dose cabergoline (up to 3.5-7 mg/week), or when vision deteriorates on medical therapy 3, 4, 1
Radiotherapy should be reserved for exceptional cases with growing prolactinomas where other treatments have failed, with the primary goal being tumor growth control rather than prolactin normalization 4, 1

Do not discontinue cabergoline prematurely; maintain treatment for at least 2 years with normalized prolactin levels and significant tumor shrinkage before considering withdrawal 1